Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
(+)-Butaclamol Hydrochloride
AOB5859
CAS No: 55528-07-9
Chemical Name: 1H-Benzo[6,7]cyclophepta [1,2,3-de]-pyrido[2,1-a]isoquinolin-3-(l, 3-(1,1-dimethylethyl)-2,3-4,4a,8,9,13b,14-octahydro-hydrochloride (3a,4aa, 13b b)
470 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $12.75 | Total: $63.75 |
| 1 | 10 | $10.80 | Total: $108.00 |
| 1 | 25 | $9.15 | Total: $228.75 |
| 1 | 50 | $7.80 | Total: $390.00 |
| 1 | 100 | $6.75 | Total: $675.00 |
Overview
Dopamine receptor antagonist
References:
- Merck Index, 11th Ed., No. 1499
- Brunderlein, et al., J. Med. Chem., v. 18, 185 (1975)
- Humber, L.G., Bruderlein, F.T., Voith, K., "Neuroleptic agents of the benzocycloheptapyrido-soquinoline series: a hypothesis on their mode of interaction with the central dopamine receptor." Mol. Pharmacol., v. 11, 833-840 (1975)
- Humber, L.G., "Butaclamol." Chronicles of Drug Discovery, Vol. 1, Chap. 3, 61 (1982)
- Lippman, et al., Psychopharmacologia, v. 42, 11 (1975)
- Lippman, et al., "Effect of butaclamol and its enantiomers upon striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats." Life Sci., v. 16, 213-224 (1975).
- Mielke, et al., Dis. Nerv. Syst., v. 36, 7 (1975)
- Mineeva, et al., "Effect of butaclamol enantiomers or tyrosine hydroxylase of the rat brain hypothalamus." [CA 102(3): 17545D] Byull. Eksp. Biol. Med., v. 98, 453 (1984)
- Pugsley, et al., "Effect of structural analogs of butaclamol (a new antipsychotic drug) on striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats." J. Physiol. Pharmacol., v. 54, 510-515 (1976).
- Pugsley, T.A. and Lippman, W., "Effect of butaclamol, a new neuroleptic on serotonergic mechanisms." J. Pharm. Pharmacol., v. 29, 135-138 (1977).
- Seeman, Pharmacological Reviews, v. 32, 229 (1980)
- Steranka, "Effects of antipsychotic drugs on the long-term effects of amphetamine on nigrostriatal dopamine neurons in iprinodole-treated rats." Naunyn-Schmiedeberg's Arch. Pharmacol., v. 325, 198 (1984)
- Voith, et al., Life Sci., v. 16, 213 (1975)
Chemical Properties
| Molecular Formula | C25H31NO · HCl |
| Molecular Weight | 397.98 |
| CAS Numbers | 55528-07-9 |
| Solubility | Soluble in water (0.25 mg/ml) or ethanol (1 mg/ml); more soluble in alcohol-water mixtures. Dissolve solid in alcohol and dilute with water. Solubility in 45% (w/v) aqueous 2-hydroxypropyl-b-cyclodextrin 5.4 mg/ml. Solutions should be freshly prepared. |
| Purity | 98% by HPLC |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Customers who bought this product also bought:
-
$49.66
